WKYMVm (trifluoroacetate salt)
(Synonyms: Trp-Lys-Tyr-Met-Val-D-Met) 目录号 : GC48360
A synthetic peptide agonist of FPR1 and FPR2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
WKYMVm is a synthetic peptide agonist of formyl peptide receptor 1 (FPR1) and FPR2, which was previously known as formyl peptide receptor-like 1 (FPRL1).1,2,3 It induces calcium mobilization in ETFR rat basophilic leukemia cells transfected with FPR1 or FPR2 when used at a concentration of 0.1 nM.1 WKYMVm stimulates chemotaxis of monocytes, dendritic cells, and natural killer (NK) cells, as well as induces superoxide production in monocytes and neutrophils, in vitro.3 In vivo, WKYMVm (8 mg/kg) reverses mucosal destruction, decreases in body weight, and colonic shortening in a mouse model of colitis induced by dextran sulfate (sodium salt) . Topical application of WKYMVm stimulates angiogenesis and accelerates re-epithelialization and granulation tissue formation in a rat model of diabetic cutaneous wounds.2
1.Le, Y., Gong, W., Li, B., et al.Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activationJ. Immunol.163(12)6777-6784(1999) 2.Kwon, Y.W., Heo, S.C., Jang, I.H., et al.Stimulation of cutaneous wound healing by an FPR2-specific peptide agonist WKYMVmWound Repair Regen.23(4)575-582(2015) 3.Kim, S.D., Kwon, S., Lee, S.K., et al.The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitisExp. Mol. Med.45(9)e40(2013)
| Cas No. | SDF | ||
| 别名 | Trp-Lys-Tyr-Met-Val-D-Met | ||
| Canonical SMILES | OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CCSC)C(N[C@@H](C(C)C)C(N[C@@H](C(N)=O)CCSC)=O)=O)=O)NC([C@H](CCCCN)NC([C@@H](N)CC2=CNC3=CC=CC=C23)=O)=O.OC(C(F)(F)F)=O | ||
| 分子式 | C41H61N9O7S2•XCF3COOH | 分子量 | 856.1 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:4): 0.20 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1681 mL | 5.8404 mL | 11.6809 mL |
| 5 mM | 0.2336 mL | 1.1681 mL | 2.3362 mL |
| 10 mM | 0.1168 mL | 0.584 mL | 1.1681 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。